Liver fibrosis

Journal of Clinical Investigation

Volumn 115, Issue 2, 2005, Pages 209-218

  Bataller, Ramón ^a   Brenner, David A ^b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ANTIFIBROTIC AGENT; ANTIOXIDANT; COLCHICINE; COLLAGEN; CORTICOSTEROID; CYTOKINE; ELASTIN; FIBRONECTIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOFUGINONE; HYALURONIC ACID; INSULIN; LAMININ; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON; PENTOXIFYLLINE; PROTEOGLYCAN; RANTES; RENIN; RIBAVIRIN; SCLEROPROTEIN; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; UNDULIN; UNINDEXED DRUG; ANGIOTENSIN II; TRANSFORMING GROWTH FACTOR BETA;

ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; APOPTOSIS; AUTOIMMUNE HEPATITIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EXTRACELLULAR MATRIX; FATTY LIVER; FIBROBLAST; FIBROGENESIS; GENE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER REGENERATION; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MYOFIBROBLAST; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STELLATE CELL; ANIMAL; METABOLISM; PATHOPHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; HUMANS; HYPERTENSION, PORTAL; LEPTIN; LIVER CIRRHOSIS; LIVER FAILURE; TRANSFORMING GROWTH FACTOR BETA;

EID: 85035392112     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24282     Document Type: Review

References (125)

1. Friedman, S.L. 2003. Liver fibrosis - from bench to bedside. J. Hepatol. 38(Suppl. 1):S38-S53.
2. Gines, P., Cardenas, A., Arroyo, V., and Rodes, J. 2004. Management of cirrhosis and ascites. N. Engl. J. Med. 350:1646-1654.
3. Popper, H., and Uenfriend, S. 1970. Hepatic fibrosis. Correlation of biochemical and morphologic investigations. Am. J. Med. 49:707-721.
4. Schaffner, F., and Klion, F.M. 1968. Chronic hepatitis. Annu. Rev. Med. 19:25-38.
5. Albanis, E., and Friedman, S.L. 2001. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin. Liver Dis. 5:315-334, v-vi.
6. Soyer, M.T., Ceballos, R., and Aldrete, J.S. 1976. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery. 79:601-604.
7. Friedman, S.L., Roll, F.J., Boyles, J., and Bissell, D.M. 1985. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc. Natl. Acad. Sci. U. S. A. 82:8681-8685.
8. Geerts, A. 2001. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver Dis. 21:311-335.
9. Friedman, S.L, et al. 1992. Isolared hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology. 15:234-243.
10. Otto, D.A., and Veech, R.L. 1980. Isolation of a lipocyte-rich fracrion from rat liver nonparenchymal cells. Adv. Exp. Med. Biol. 132:509-517.
11. Rockey, D.C., Boyles, J.K., Gabbiani, G., and Friedman, S.L. 1992. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J. Submicrosc. Cytol. Pathol. 24:193-203.
12. Pinzani, M., Gesualdo, L., Sabbah, G.M., and Abboud, H.E. 1989. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fatstoring cells. J. Clin. Invest. 84:1786-1793.
13. Wasser, S., and Tan, C.E. 1999. Experimental models of hepatic fibrosis in the rat. Ann. Acad. Med. Singapore. 28:109-111.
14. Ramadori, G., and Saile, B. 2004. Portal tract fibrogenesis in the liver. Lab. Invest. 84:153-159.
15. Forbes, S.J., et al. 2004. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology. 126:955-963.
16. Poynard, T., et al. 2000. Natural history of HCV infection. Baillieres Best Pract. Res. Clin. Gastroenterol. 14:211-228.
17. Poynard, T., Bedossa, P., and Opolon, P. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 349:825-832.
18. Bataller, R., North, K.E., and Brenner, D.A. 2003. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology. 37:493-503.
19. Hammel, P., et al. 2001. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N. Engl. J. Med. 344:418-423.
20. Bataller, R., and Brenner, D.A. 2001. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis. 21:437-451.
21. Brunt, E.M. 2004. Nonalcoholic steatohepatitis. Semin. Liver Dis. 24:3-20.
22. Ludwig, J., Viggiano, T.R., McGill, D.B., and Oh, B.J. 1980. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55:434-438.
23. Davis, G.L., Albright, J.E., Cook, S.F., and Rosen-berg, D.M. 2003. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 9:331-338.
24. Berenguer, M., et al. 2003. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl. 9:228-235.
25. Afdhal, N.H., and Nunes, D. 2004. Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol. 99:1160-1174.
26. Thampanitchawong, P., and Piratvisuth, T. 1999. Liver biopsy: complications and risk factors. World J. Gastroenterol. 5:301-304.
27. Regev, A., et al. 2002. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 97:2614-2618.
28. Imbert-Bismut, F., et al. 2001. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 357:1069-1075.
29. Forns, X., et al. 2002. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 36:986-992.
30. Fonrana, R.J., and Lok, A.S. 2002. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 36:S57-S64.
31. Hirata, M., Akbar, S.M., Horiike, N., and Onji, M. 2001. Non invasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus. Eur. J. Clin. Invest. 31:528-535.
32. Callewaert, N., et al. 2004. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 10:429-434.
33. Pinzani, M. 1999. Liver fibrosis. Springer Semin. Immunopathol. 21:475-490.
34. Benyon, R.C., and Iredale, J.P. 2000. Is liver fibrosis reversible? Gut. 46:443-446.
35. Arthur, M.J. 2000. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 279:G245-G249.
36. Gabele, E., Brenner, D.A., and Rippe, R.A. 2003. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front. Biosci. 8:D69-D77.
37. Milani, S., et al. 1990. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology. 98:175-184.
38. Marra, F. 1999. Hepatic stellate cells and the regulation of liver inflammation. J. Hepatol. 31:1120-1130.
39. Lindquist, J.N., Marzluff, W.F., and Stefanovic, B. 2000. Fibrogenesis. III. Posttranscriptional regulation of type I collagen. Am. J. Physiol. Gastrointest. Liver Physiol. 279:G471-G476.
40. Lindquist, J.N., Parsons, C.J., Stefanovic, B., and Brenner, D.A. 2004. Regulation of alpha1(1) collagen messenger RNA decay by interactions with alphaCP at the 3′-untranslatcd region. J. Biol. Chem. 279:23822-23829.
41. Sato, M., Suzuki, S., and Senoo, H. 2003. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct. Funct. 28:105-112.
42. Oben, J.A., Yang, S., Lin, H., Ono, M., and Diehl, A.M. 2003. Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells. Biochem. Biophys. Res. Commun. 302:685-690.
43. Kinnman, N., and Housset, C. 2002. Peribiliary myofibroblasts in biliary type liver fibrosis. Front. Biosci. 7:d496-d503.
44. Magness, S.T., Bataller, R., Yang, L., and Brenner, D.A. 2004. A dual reporter gene transgenic mouse demonstrates heterognity in hepatic fibrogenic cell populations. Hepatology. 40:1151-1159.
45. Knittel, T., et al. 1999. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology. 117:1205-1221.
46. Suskind, D.L., and Muench, M.O. 2004. Searching for common stem cells of the hepatic and hematopoietic systems in the human fetal liver: CD34+ cytokeratin 7/8+ cells express markers for stellate cells. J. Hepatol. 40:261-268.
47. Philllips, R.J., et al. 2004. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 114:438-446. doi:10.I172/ JCI200420997.
48. Kalluri, R., and Neilson, E.G. 2003. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Infest. 112:1776-1784. doi:10.I172/ JCI200320530.
49. Kmiec, Z. 2001. Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Biol. 161:III-XIII, 1-151.
50. Higuchi, H., and Gores, G.J. 2003. Mechanisms of liver injury: an overview. Curr. Mol. Med. 3:483-490.
51. Canbay, A., Friedman, S., and Gores, G.J. 2004. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 39:273-278.
52. Casini, A., et al. 1997. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology. 25:361-367.
53. Vinas, O., et al. 2003. Human hepatic stellate cells show features of antigen-presenring cells and stimulate lymphocyte proliferation. Hepatology. 38:919-929.
54. Maher, J.J. 2001. Interactions between hepatic stellate cells and the immune system. Semin. Liver Dis. 21:417-426.
55. Shi, Z., Wakil, A.E., and Rockey, D.C. 1997. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. U. S. A. 94:10663-10668.
56. Naito, M., Hasegawa, G., Ebe, Y., and Yamamoto, T. 2004. Differentiation and function of Kupffer cells. Med. Electron Microsc. 37:16-28.
57. Thurman, R.G. 1998. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am. J. Physiol. 275:G605-G611.
58. Gressner, A.M., Weiskirchen, R., Breitkopf, K., and Dooley, S. 2002. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 7:d793-d807.
59. Olaso, E., et al. 2001. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J. Clin. Invest. 108:1369-1378. doi:10.I172/JCI200112373.
60. Takehara, T., et al. 2004. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. 127:1189-1197.
61. Canbay, A., et al. 2002. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology. 123:1323-1330.
62. Safadi, R., et al. 2004. Immune stimulation of hepatic fibrogenesis by CDS cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology. 127:870-882.
63. Sahai, A., Malladi, P., Melin-Aldana, H., Green, R.M., and Whitington, P.F. 2004. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am. J. Physiol. Gastrointest. Liver Physiol. 287:G264-G273.
64. Yoshida, T., et al. 2004. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J. Exp. Med. 199:1701-1707.
65. Streetz, K.L., et al. 2003. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology. 38:218-229.
66. Bataller, R., et al. 2003. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 112:1383-1394. doi:10.1172/JC1200318212.
67. Oben, J.A., et al. 2004. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut. 53:438-445.
68. Yu, C., et al. 2003. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am. J. Pathol. 163:1653-1662.
69. Kamada, Y., et al. 2003. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 125:1796-1807.
70. Kanno, K., Tazuma, S., and Chayama. K. 2003. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem. Biophys. Res. Commun. 308:177-183.
71. Ueberham, E., et al. 2003. Conditional tetracycline-regulated expression of TGE-beta I in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology. 37:1067-1078.
72. Yoshiji, H., et al. 2002. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology. 36:850-860.
73. Aganval, D.P. 2001. Genetic polymorphisms of alcohol metabolizing enzymes. Pathol. Biol. 49:703-709.
74. Degoul, F., et al. 2001. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology. 120:1468-1474.
75. Jarvelainen, H.A., et al. 2001. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology. 33:1148-1153.
76. Donaldson, P., et al. 2001. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut. 48:397-402.
77. Corpechot, C., et al. 2001. Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J. Hepatol. 35:324-328.
78. Schuppan, D., Krebs, A., Bauer, M., and Hahn, E.G. 2003. Hepatitis C and liver fibrosis. Cell Death Differ. 10(Suppl. 1):S59-S67.
79. Powell, E.E., et al. 2000. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 31:828-833.
80. Sasaki, K., et al. 2000. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand. J. Gastroenterol. 35:960-965.
81. Akuta, N., et al. 2001. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen ptocessing 2(TAP2}*0201 allele. J. Med. Virol. 64:109-116.
82. Martinelli, A.L., et al. 2000. Are haemochtomatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol. 102:152-156.
83. Thorburn, D., et al. 2002. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut. 50:248-252.
84. Day, C.P. 2004. The potential role of genes in nonalcoholic fatty liver disease. Clin. Liver Dis. 8:673-691, xi.
85. Marra, F. 2002. Chemokines in liver inflammation and fibrosis. Front. Biosci. 7:d1899-d1914.
86. Schwabe, R.F., Bataller, R., and Brenner. D.A. 2003. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am. J. Physiol. Gastrointest. Liver Physiol. 285:G949-G958.
87. Shek, F.W., and Benyon, R.C. 2004. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur. J. Gastroenterol. Hepatol. 16:123-126.
88. Borkham-Kamphorst, E., Stoll, D., Gressner, A.M., and Weiskitchen, R. 2004. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem. Biophys. Res. Commun. 321:413-423.
89. Williams, E.J.,et al. 2001. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut. 49:577-583.
90. Cho, J.J., et al. 2000. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology. 118:1169-1178.
91. Paizis, G., et al. 2002. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology. 123:1667-1676.
92. Bataller, R., et al. 2003. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 125:117-125.
93. Jonsson, J.R., et al. 2001. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 121:148-155.
94. Paizis, G., et al. 2001. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J. Hepatol 35:376-385.
95. Ramalho, L.N., et al. 2002. Effect of losartan, an angiotensin 11 antagonist, on secondary biliary cirrhosis. Hepatogastroenterology. 49:1499-1502.
96. Wei, H.S., et al. 2000. The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl(4). World J. Gastroenterol. 6:824-828.
97. Wei, M.S., et al. 2000. Effects of ATI receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). World J. Gastroenterol. 6:540-545.
98. Tuncer, I., Ozbek, H., Ugras, S., and Bayram, I. 2003. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp. Toxicol. Pathol. 55:159-166.
99. Bataller, R., et al. 2000. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 118:1149-1156.
100. Bataller, R., et al. 2003. Prolonged infusion of angiorensin 11 into normal rats induces stellate cell activation and proinflammatory events in liver. Am. J. Physiol. Gastrointest. Liver Physiol. 285:G642-G651.
101. Wheeler, M.D., et al. 2001. The role of Kupffer cell oxidanr production in early ethanol-induced liver disease. Free Radic. Biol. Med. 31:1544-1549.
102. Kono, H., et al. 2000. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J. Clin. Invest. 106:867-872.
103. Marra, F. 2002. Leptin and liver fibrosis: a matter of fat. Gastroenterology. 122:1529-1532.
104. Ikejima, K., et al. 2002. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 122:1399-1410.
105. Ortiz, V., Berenguer, M., Rayon, J.M., Carrasco, D., and Berenguer, J. 2002. Contribution of obesity to hepatitis C-related fibrosis progression. Am. J. Gastroenterol. 97:2408-2414.
106. Pinzani, M. 2002. PDGF and signal transduction in hepatic stellate cells. Front, Biosci. 7:d1720-d1726.
107. Marra, F.,et al. 1999. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology. 30:951-958.
108. Schwabe, R.F., et al. 2004. Differential requirement for c-Jun NH2-terminal kinase in TNFalpha- and Fas-mediated apoptosis in hepatocytes. FASEB J. 18:720-722.
109. Schwabe, R.F., Schnabl, B., Kweon, Y.O., and Brenner, D.A. 2001. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J. Immunol 166:6812-6819.
110. Schnabl, B., et al. 2001. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 34:89-100.
111. Dooley, S., et al. 2003. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology. 125:178-191.
112. Marra, F., et al. 2000. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 119:466-478.
113. Galli, A., et al. 2002. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 122:1924-1940.
114. Boya, P., et al. 2001. Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression. Hepatology. 34:1041-1048.
115. Rippe, R.A., Schrum, L.W., Stefanovic, B., Solis-Herruzo, J.A., and Brenner, D.A. 1999. NF-kappaB inhibits expression of the alpha1(I) collagen gene. DNA Cell Biol. 18:751-761.
116. Mann, D.A., and Smart, D.E. 2002. Transcriptional regulation of hepatic stellate cell activation. Gut. 50:891-896.
117. Paik, Y.H., et al. 2003. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 37:1043-1055.
118. Canbay, A., et al. 2003. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J. Clin. Invest. 112:152-159. doi: 10.1172/JCI200317740.
119. Maher, J.J., Zia, S., and Tzagarakis, C. 1994. Acetaldehyde-induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: studies with rat lipocytes and fibroblasts. Alcohol Clin. Exp. Res. 18:403-409.
120. Bataller, R., Paik. Y.H., Lindquist, J.N., Lemasters, J.J., and Brenner, D.A. 2004. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 126:529-540.
121. Wanless, I.R., and Shiota, K. 2004. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis. 24:99-106.
122. Arthur, M.J. 2002. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 122.1525-1528.
123. Issa, R., et al. 2004. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated wirh matrix cross-linking. Gastroenterology. 126:1795-1808.
124. Pares, A., Caballeria, J., Bruguera, M., Torres, M., and Rodes, J. 1986. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J. Hepatol. 2:33-42.
125. Dixon, J.B., Bhathal, P.S., Hughes, N.R., and O'Brien, P.E. 2004. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 39:1647-1654.